Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep650 | Pituitary and Neuroendocrinology | ECE2022

Hypopituitarism in patients with pituitary macroadenomas - the prevalence and prognostic factors

Krivosheeva Yulya , Ilovayskaya Irena

Hypopituitarism due to pituitary lesions may have unclear clinical manifestations, and for its diagnosis it is necessary to conduct a hormonal examination. There are clinical recommendations to conduct a hormonal investigation in all cases of pituitary tumors > 6 mm that seems to be uncertain.The objective to evaluate the frequency of hypopituitarism in patients with pituitary macroadenomas with different hormonal activity and to identify its possibl...

ea0081ep782 | Pituitary and Neuroendocrinology | ECE2022

Screening of IGF-1 level in patients with Prolactinomas

Ukhanova Yulia , Ilovayskaya Irena

Objective: to determine the need for screening for IGF-1 levels in patients with prolactinomas and without obvious symptoms of acromegaly. Matherials and methods: A pilot cross-sectional study, based on the analysis of medical records of patients with confirmed prolactinoma, who applied to the Moscow Regional Research and Clinical Institute named by M.F. Vladimirsky. A total of 88 patients were included in the study. The frequency of studying the level o...

ea0081ep857 | Reproductive and Developmental Endocrinology | ECE2022

Clinical and biochemical markers of premature ageing in young hypopituitary women with untreated hypogonadism

Ilovayskaya Irena , Loktionova Anna

Hypogonadotropic hypogonadism as a part of hypopituitarism can be a cause of persistent amenorrhea and hypoestrogenemia in women of reproductive age as it is observed in postmenopause. We know that premature and early menopause leads to accelerated aging with such markers as decreased quality of life, phyco-emotional deprivation, dyslipidemia, bone mineral density and others. We hypothesized that untreated hypogonadism in young women with hypopituitarism could cause premature ...

ea0090ep729 | Pituitary and Neuroendocrinology | ECE2023

Features of pituitary macroadenomas with one size less than 10 mm

Krivosheeva Yulya , Ilovayskaya Irena

There are clinical recommendations to conduct a hormonal investigation in all cases of pituitary tumors > 6 mm in size that seems to be uncertain.The objective: To reveal features of pituitary macroadenomas with at least one size less than 10 mmThe materials and methods: We have analyzed medical records of 380 newly diagnosed patients with pituitary macroadenomas before any treatment: 162 non-functioning adenomas (NFAs), 74 pro...

ea0090ep882 | Pituitary and Neuroendocrinology | ECE2023

Clinical case of partially resistant prolactinoma

Ukhanova Yulia , Ilovayskaya Irena

In real practice, pituitary adenomas may have non-specific clinical manifestations. Patients are consulted by doctors of various specialties, but not endocrinologists. In confirmation of this we would like to present a Clinical case Male patient D. experienced severe headache at the age 39 y.o., was consulted by the neurologist. MRI demonstrated a pituitary macroadenoma 35x36x36 mm in size (22680 mm3) with supra-para-infrasellar growth. The neurosurgeon recommended surgical tr...

ea0073aep508 | Pituitary and Neuroendocrinology | ECE2021

Female central hypogonadism with or without organic pituitary lesions: diagnostic value of LH and FSH basal levels

Loktionova Anna , Ilovayskaya Irena

Central hypogonadism (CH) is a syndrome that can be revealed in women with hypoestrogenic amenorrhea due to the lack of normal response of gonadotropins to the hypoestrogenemia. CH can be caused by organic lesion of the hypothalamo-pituitary region or has idiopathic character – without any structural background. This syndrome is often called ’hypogonadotropic hypogonadism’, but LH and FSH levels within ’normal’ laboratory range does not exclude CH beca...

ea0081ep655 | Pituitary and Neuroendocrinology | ECE2022

Somatostatin analogues in the treatment of a patient with acromegaly - possible positive effects on concomitant epilepsy (a clinical case)

Seferyan Sergey , Zakharova Polina , Ilovayskaya Irena

Somatostatin may act as a neurotransmitter in the neural network. It`s associated with a possible long-term effect on calcium channels and, as a result, on the membrane potential of the cell. Bradycardia due to somatostatin analogues’ use could be a clinical demonstration of such effect. We would like to present a clinical case of a female patient with acromegaly and possible positive effect of octreotide treatment on concomitant epilepsy. From 2000 (age 40) a woman...

ea0049gp193 | Pituitary & endocrine Tumours | ECE2017

Amenorrhea without vasomotor symptoms in women over 40: A sign of pathological hyperprolactinemia?

Ilovayskaya Irena , Dreval Alexader , Krivosheeva Yulia

Background: Hyperprolactinemia is often seen in women of reproductive age (20–35 years), most often due to microprolactinoma. However, prolactinomas do occur in older women.Objective: To analyze clinical features of hyperprolactinemia in women >40 yearsMaterial and methods: Clinical and biochemical data of 185 women with pathological hyperprolactinemia were analyzed.Results: Seventy (37.8%) patients ...

ea0070oc4.1 | Pituitary and Neuroendocrinology | ECE2020

Quantitative mRNA expression of PROK2, DUSP6, and WDR11 in peripheral blood as diagnostic criteria for central hypogonadism

Loktionova Anna , Ilovayskaya Irena , Nefedova Lidia

Central hypogonadism (CH) is a syndrome that can be diagnosed in women with hypoestrogenic amenorrhea and a lack of normal response of gonadotropins to hypoestrogenemia in the absence of other reasons. To date, about 50 genes were reported as a possible reason for this condition, but the genetic basis is still unknown for approximately a half of CH cases.Patients and Methods: Some of the CH-related genes are expressing in leukocytes of peripheral blood: ...

ea0081ep4 | Adrenal and Cardiovascular Endocrinology | ECE2022

Clinical-laboratory and morphological predictors of pheochromocytoma progression

Motrenko Anna , Britvin Timur , Ilovayskaya Irena , Gurevch Larisa

According to the 4th edition of the WHO classification of endocrine organ tumors (2017), all pheochromocytomas are classified as malignant tumors (ICD-O code 8700/3). However, in the literature there are no unambiguous data on the significance of clinical and laboratory predictors of the aggressiveness of pheochromocytoma. The aim of the study was to verify possible predictors of pheo-progression using clinical data, the results of laboratory and instrumental examination (incl...